Ibrutinib is a selective covalent Bruton’s tyrosine kinase (BTK) inhibitor, which could penetrate blood-brain barrier [13] and approved by the Food and Drug Administration (FDA) in 2013 as a treatment of several hematological malignancies. Here, BTK is linked to hematologic disorder.